Aranidipine

CAS No. 86780-90-7

Aranidipine( MPC1304 )

Catalog No. M20129 CAS No. 86780-90-7

Aranidipine (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 42 In Stock
10MG 76 In Stock
25MG 138 In Stock
50MG 233 In Stock
100MG 393 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Aranidipine
  • Note
    Research use only, not for human use.
  • Brief Description
    Aranidipine (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects.
  • Description
    Aranidipine (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects.(In Vivo):Aranidipine (MPC-1304) is a new Ca2+ channel antagonist in spontaneously hypertensive rats. Following oral administration of Aranidipine at doses of 3 and 10 mg/kg to spontaneously hypertensive rats (SHR), there are significant decreases in Bmax values for specific [3H](+)-PN 200-110 binding to myocardial membranes compared to the control values. The Bmax values at 1 h (3 mg/kg), 1 and 6 h (10 mg/kg) are significantly decreased (47.7, 48.9 and 25.8%, respectively) compared to the control values. The effect is greatest at 1 h and decreases with time. The Bmax values at 6 h (3 mg/kg) and 12 or 24 h (10 mg/kg) after the oral administration of Aranidipine are not significantly different from the control values, suggesting the disappearance of the effect of Aranidipine. The Kd values for myocardial [3H](+)-PN 200-110 binding are unaltered by oral administration of Aranidipine.
  • In Vitro
    ——
  • In Vivo
    Aranidipine (MPC-1304) is a new Ca2+ channel antagonist in spontaneously hypertensive rats. Following oral administration of Aranidipine at doses of 3 and 10 mg/kg to spontaneously hypertensive rats (SHR), there are significant decreases in Bmax values for specific [3H](+)-PN 200-110 binding to myocardial membranes compared to the control values. The Bmax values at 1 h (3 mg/kg), 1 and 6 h (10 mg/kg) are significantly decreased (47.7, 48.9 and 25.8%, respectively) compared to the control values. The effect is greatest at 1 h and decreases with time. The Bmax values at 6 h (3 mg/kg) and 12 or 24 h (10 mg/kg) after the oral administration of Aranidipine are not significantly different from the control values, suggesting the disappearance of the effect of Aranidipine. The Kd values for myocardial [3H](+)-PN 200-110 binding are unaltered by oral administration of Aranidipine.
  • Synonyms
    MPC1304
  • Pathway
    GPCR/G Protein
  • Target
    Calcium Channel
  • Recptor
    Calcium Channel
  • Research Area
    Cardiovascular Disease
  • Indication
    Angina pectoris and high blood pressure

Chemical Information

  • CAS Number
    86780-90-7
  • Formula Weight
    388.37
  • Molecular Formula
    C19H20N2O7
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)=O
  • Chemical Name
    (+-)-Acetonyl methyl 14-dihydro-26-dimethyl-4-(o-nitrophenyl)-35-pyridinedicarboxylate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Masumiya H et al. Inhibition of T-type and L-type Ca(2+) currents by aranidipine a novel dihydropyridine Ca(2+) antagonist. Pharmacology. 2000 Aug;61(2):57-61.
molnova catalog
related products
  • Levetiracetam

    Levetiracetam(UCB L059) is a novel anticonvulsant with antihyperalgesic efficacy in inflammatory pain.

  • ML335

    ML335 is a selective activator of both TREK-1 and TREK-2.

  • Caldaret HCl

    Caldaret HCl is an intracellular Ca2+ modulator that regulates calcium homeostasis at the sarcoplasmic reticulum and cell membrane, and can be used to study acute myocardial infarction and heart failure.